Teva and Mylan Settle Copaxone® Patent Litigation in France, the UK and the Netherlands
PITTSBURGH, Nov. 25, 2013 /PRNewswire/ -- Teva Pharmaceutical Industries (NYSE: TEVA) and Mylan Inc. (NASDAQ: MYL) today announce that certain of their affiliates have agreed to settle and dismiss pending patent litigation involving Copaxone® (glatiramer acetate) in the United Kingdom, the Netherlands and France relating to non-infringement and the validity of European Patent 0,762,888, which expires in May 2015. The terms of the settlement are confidential.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,200 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.
More by this Source
Mylan Launches First Generic ORTHO EVRA® Patch
Apr 16, 2014, 16:13 ET
Mylan Announces Settlement Agreement for First-to-File Generess® Fe
Apr 15, 2014, 10:20 ET
Mylan Launches Generic Lunesta® Tablets
Apr 15, 2014, 10:08 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.